Eagle Pharmaceuticals, Inc.
Eagle Pharmaceuticals develops and commercializes products for central nervous system, metabolic critical care, oncology, and more. Products include Ryanodex, Belrapzo, Bendeka, EP-4104, PEMFEXY, EA-114, and Vasopressin injection. The company has licensing agreements with Combioxin, SA, and AOP Orphan Pharmaceuticals GmbH. Eagle also collaborates with Tyme Technologies for the development of SM-88 to treat breast cancer and sarcomas.
Overview
Strengths
- With an appreciation Potential of 400.00%, based on our fundamental analysis, it suggests the stock may be undervalued.
- Current Price to Earnings Ratio (0.35) is lower than the sector mean (289.29).
- Price to book ratio (0.05) is lower than the sector mean (733.70).
- The company has low debt. Net Debt to EBITDA Ratio is 0.09 and it is lower than the sector mean.
- EV/EBITDA (0.25) is lower than the sector mean (51.86).
- EV/EBIT (0.30) is lower than the sector mean.
- Price to free cash flow (0.25) is lower than the sector mean.
- Strong EBITDA Margin of 24.48%.
Weaknesses
- Earnings are projected to decline (-10.0% per year).
Key Financial Data